Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Natco Pharma Ltd, founded in the year 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 4,126.90 | 2,811.70 | 2,043.80 | 2,155.70 | 2,022.40 |
Total Expenses | 2,453.40 | 1,949.80 | 1,841.60 | 1,576.10 | 1,453.70 |
Profit Before Tax | 1,673.50 | 861.90 | 202.20 | 579.60 | 568.70 |
Profit After Tax | 1,388.30 | 715.30 | 170 | 442.40 | 458.10 |
Operating Profit after Depreciation | 1,692.70 | 876.40 | 219.90 | 592.90 | 590.20 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2,490.80 | 2,426.90 | 2,311.80 | 2,023.20 | 1,584.40 |
Total Non Current Assets | 2,882.80 | 2,657.10 | 2,622.40 | 2,447.10 | 2,262.20 |
Total Current Assets | 4,023.50 | 3,000.30 | 2,486.70 | 2,344.80 | 2,325.60 |
TOTAL ASSETS | 6,906.30 | 5,657.40 | 5,109.10 | 4,791.90 | 4,587.80 |
Total Shareholder's Fund | 5,853.10 | 4,873.80 | 4,263.60 | 4,121.60 | 3,773.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1,211.60 | 849.10 | 46.50 | 298.80 | 417.30 |
Net Cash used in Investing Activities | -1,026.20 | -465.30 | 4 | -107.10 | -175 |
Net Cash used in Financing Activities | -246.90 | -363 | 34.80 | -185.70 | -250.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 3,673.60 | 2,436.50 | 1,862.40 | 1,754.60 | 1,914 |
Total Expenses | 2,118.30 | 1,665.80 | 1,706.50 | 1,362.40 | 1,330.90 |
Profit Before Tax | 1,555.30 | 770.70 | 155.90 | 392.20 | 583.10 |
Profit After Tax | 1,306.60 | 637.10 | 139.10 | 309.50 | 474.50 |
Operating Profit after Depreciation | 1,569.80 | 779.30 | 169.20 | 403.50 | 603.70 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2,286.70 | 2,233.80 | 2,174.20 | 2,005.90 | 1,574.50 |
Total Non Current Assets | 3,143.60 | 2,893.20 | 2,810.30 | 2,584 | 2,406.80 |
Total Current Assets | 3,410.40 | 2,494.70 | 2,167.70 | 2,168.50 | 2,239.90 |
TOTAL ASSETS | 6,554 | 5,387.90 | 4,978 | 4,752.50 | 4,646.70 |
Total Shareholder's Fund | 5,592.30 | 4,702 | 4,191.90 | 4,091.10 | 3,869.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1,196.40 | 784.40 | 57.70 | 183.50 | 422.50 |
Net Cash used in Investing Activities | -960.50 | -436.60 | -92.50 | -3.20 | -165 |
Net Cash used in Financing Activities | -237.30 | -346.80 | 35.60 | -183.10 | -261.10 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 474.80 | 1,371.10 | 1,362.60 | 1,068.30 | 758.60 |
Total Expenses | 436 | 566.80 | 557.80 | 571 | 490.50 |
Profit Before Tax | 163.70 | 818.20 | 803.60 | 477.60 | 256.30 |
Profit After Tax | 132.40 | 676.50 | 668.50 | 386.30 | 212.70 |
Operating Profit after Depreciation | 215.10 | 868.10 | 852.90 | 539.30 | 305.10 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 407.60 | 1,292.60 | 1,236.90 | 964.80 | 625.30 |
Total Expenses | 378.20 | 501.90 | 473.90 | 512.10 | 387 |
Profit Before Tax | 150.30 | 796.90 | 758 | 432.50 | 223.60 |
Profit After Tax | 124.90 | 661.10 | 636.30 | 349.10 | 192 |
Operating Profit after Depreciation | 197.40 | 842.10 | 802.80 | 488.60 | 267.80 |
₹1.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Natco Pharma Ltd | ₹883.70 | ₹15,827.94 |
Sun Pharmaceuticals Industries Ltd | ₹1,704.65 | ₹4,09,002.64 |
Divis Laboratories Ltd | ₹5,836.45 | ₹1,54,939.41 |
Cipla Ltd | ₹1,459.05 | ₹1,17,834.93 |
Torrent Pharmaceuticals Ltd | ₹3,011.50 | ₹1,01,918.27 |
Dr Reddys Laboratories Ltd | ₹1,195.85 | ₹99,784.59 |
Orchid Pharma Ltd, Vijaya Diagnostic Centre Ltd, FDC Ltd and Aegis Logistics Ltd are among the other losers in the BSE's 'A' group today, 13 February 2025.
13 Feb 2025, 03:00 pm
Natco Pharma Ltd is quoting at Rs 997, down 18.2% on the day as on 13:19 IST on the NSE. The stock jumped 11.51% in last one year as compared to a 6.07% rally in NIFTY and a 16.07% spurt in the Nifty Pharma index.
13 Feb 2025, 01:35 pm
Natco Pharma tanked 17.91% to Rs 998.70 after the company's consolidated net profit declined 37.75% to Rs 132.4 crore on 37.41% drop in revenue from operations to Rs 474.8 crore in Q3 FY25 over Q3 FY24.
13 Feb 2025, 11:11 am
Of Rs.1.50 per share
12 Feb 2025, 04:43 pm
Natco Pharma said that it has received final approval of its ANDA for Bosentan tablets for oral suspension (TFOS), which is a generic version of Tracleer by Actelion Pharmaceuticals US Inc.
10 Feb 2025, 10:39 am
View More